As part of its Single Technology Appraisal process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of ibrutinib (Janssen) to submit evidence on the clinical effectiveness and cost effectiveness of ibrutinib for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL). The School of Health and Related Research Technology Assessment Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG). The ERG produced a critical review of the evidence contained within the company's submission to NICE. The clinical effectiveness evidence for ibrutinib included one randomised controlled trial comparing ibrutinib and temsirolimus and two single-arm studies. The company's indirect comparison of ibrutinib versus rituximab plus chemotherapy (R-chemo) produced a hazard ratio (HR) for progression-free survival (PFS) of 0.28. The ERG's random effects network meta-analysis (NMA) indicated that the treatment effect on PFS was highly uncertain (HR 0.27; 95% credible interval (CrI) 0.06-1.26). The company's Markov model assessed the cost effectiveness of ibrutinib versus R-chemo for the treatment of R/R MCL from the perspective of the National Health Service (NHS) and Personal Social Services over a lifetime horizon. Based on a re-run of the company's model by the ERG, the incremental cost-effectiveness ratio (ICER) for ibrutinib versus R-chemo [including the company's original patient access scheme (PAS)] was expected to be £76,014 per quality-adjusted life-year (QALY) gained. The ERG had several concerns regarding the company's model structure and the evidence used to inform its parameters. The ERG's preferred analysis, which used the ERG's NMA and the observed Kaplan-Meier curve for time to ibrutinib discontinuation and excluded long-term disutilities for R-chemo, produced ICERs of £63,340 per QALY gained for the overall R/R MCL population and of £44,711 per QALY gained for patients with one prior treatment. Following an updated PAS and consideration of evidence from a later data-cut of the RAY trial, the appraisal committee concluded that the most plausible ICER for the one prior treatment subgroup was likely to be lower than the company's estimate of £49,848 per QALY gained. The company's ICER for the overall R/R MCL population was higher, at £62,650 per QALY gained. The committee recommended ibrutinib as an option for treating R/R MCL in adults only if they have received only one previous line of therapy and the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England. The committee concluded that the most plausible ICER for the one prior therapy subgroup was likely to be lower than £49,848 per QALY gained. Ibrutinib was recommended as an option for treating R/R MCL in adults only if they have received only one previous line of therapy and the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England
Introduction
Health technologies must be shown to be clinically effective and to represent a cost-effective use of resources to be recommended for use within the National Health Service (NHS) in England. The National Institute for Health and Care Excellence (NICE) is an independent organisation responsible for providing national guidance on promoting good health, and preventing and treating ill health, in priority areas with significant impact. The NICE Single Technology Appraisal (STA) process usually covers new technologies soon after they have received UK marketing authorisation and is specifically designed for the appraisal of a single health technology within a single indication [1] . Within the STA process, the manufacturer of a technology provides NICE with a written submission containing relevant clinical effectiveness evidence alongside a health economic model that summarises the company's estimates of the cost effectiveness of the technology. The Evidence Review Group (ERG), an external academic organisation independent of NICE, reviews the submission with advice from clinical specialists and produces an ERG report. The NICE appraisal committee (AC) considers the company's submission (CS), the ERG report and testimony from experts and other stakeholders and formulates preliminary guidance-the appraisal consultation document (ACD)-which indicates the initial decision of the AC regarding the recommendation (or not) of the intervention. Stakeholders are subsequently invited to comment on the submitted evidence and the ACD, after which an ACD may be produced or a final appraisal determination (FAD) issued, which is open to appeal. An ACD is not produced when the intervention is recommended without restriction; in such instances, an FAD is produced directly. This paper presents a summary of the ERG report produced by the School of Health and Related Research Technology Assessment Group at the University of Sheffield [2] and the NICE FAD [3] for the STA of ibrutinib for the treatment of patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). It also covers the subsequent development of the NICE guidance for the use of this drug in England [4] . Full details of all relevant appraisal documents can be found on the NICE website [5] .
The Decision Problem
Mantle cell lymphoma is a B-cell malignancy with unique biological, pathological and clinical features that accounts for approximately 3-10% of all non-Hodgkin lymphomas (NHLs). MCL typically arises in older adults, with a median age of presentation between 60 and 65 years of age. Approximately 75% of patients with MCL are male. The disease is rare: the company estimated there would be 356 patients with R/R MCL in England, Wales and Northern Ireland in 2017 [6] . MCL is characterised by an aggressive clinical disease course but features a pattern of resistant and relapsing disease, thereby rendering it incurable with standard therapy. The prognosis for patients with MCL is very poor compared with other forms of NHL; after excluding patients for whom autologous stem cell transplantation (ASCT) is a treatment option, median survival for patients with MCL following first relapse is typically reported to be approximately 1-2 years [7] but may be lower.
Current Treatment
There is no standard of care for patients with R/R MCL, and the disease remains very difficult to manage. The British Committee for Standards in Haematology (BCSH) guidelines [7] note that the choice of therapy at relapse will be determined by patient age, performance status, bone marrow reserve, initial therapy and history of infections. For patients who have not received transplantation as first-line therapy but are sufficiently fit for such therapy following relapse, ASCT may be considered as a clinical option [7] . However, this is not a common scenario, as most patients who are suitable for an autograft will have received it first line when it is best tolerated and likely to be most effective. For older and/or less fit patients, a range of systemic chemotherapy regimens may be considered, provided the patient is sufficiently fit to receive them. Treatment typically involves chemotherapy with or without rituximab and may include such regimens as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone), R-bendamustine (rituximab and bendamustine), FCR (rituximab, fludarabine and cyclophosphamide), R-CVP (rituximab, cyclophosphamide, vincristine and prednisolone) or R-chlorambucil (rituximab and chlorambucil). None of these therapies are specifically licensed for the treatment of R/R MCL. Guidelines published by the European Society for Medical Oncology (ESMO) discourage the use of R-CVP and FCR because of inferior response rates and long-lasting myelosuppression [8] . The BCSH guidelines for MCL report that several other regimens have been shown to have activity in R/R MCL, including (1) bortezomib; (2) bortezomib-gemcitabine; (3) bortezomib-rituximab; (4) temsirolimus; (5) rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM); (6) fludarabine; (7) fludarabine-cyclophosphamide; (8) fludarabine-cyclophosphamide ± rituximab; (9) cladribine; (10) gemcitabine-dexamethasone; (11) gemcitabine-dexamethasone-cisplatin; (12) lenalidomide; (13) thalidomide-rituximab and (14) prednisone, etoposide, procarbazine and cyclophosphamide (PEP-C)/thalidomide/ rituximab [7] . Where patients have received one previous line of treatment, a different regimen would typically be used following relapse. While ESMO recommends targeted therapies such as temsirolimus, bortezomib and lenalidomide [8] , temsirolimus is not currently used in England, bortezomib is recommended only in untreated MCL and lenalidomide is available only via a compassionate use programme [6] .
In February 2016, NICE issued a final scope to appraise the clinical effectiveness and cost effectiveness of ibrutinib for the treatment of R/R MCL [9] .
Independent Evidence Review Group (ERG) Review
The company (Janssen) provided a submission to NICE on the clinical effectiveness and cost effectiveness of ibrutinib for the treatment of R/R MCL [6] . The ERG critically appraised this submission and identified areas requiring clarification, for which the company provided additional evidence prior to completion of the ERG report [10] .
Clinical Evidence Submitted by the Company
Clinical-effectiveness data were taken from three studies: one randomised controlled trial (RCT) [RAY (MCL3001)] and two single-arm studies [PCYC1104 and SPARK (MCL2001)] [11] [12] [13] . One additional study of temsirolimus versus physicians' choice of therapy (the OPTIMAL study [14] ) was included in an indirect comparison of ibrutinib versus single-agent chemotherapy. At the time of the CS, median overall survival (OS) had not been reached in the ibrutinib arm of the RAY study (n = 139) or in the SPARK study (n = 120). In PCYC1104 (n = 111), median OS was 22.5 months.
Median progression-free survival (PFS) for ibrutinib-treated patients was 14.6 months in the RAY study, 13.0 months in the final analysis of PCYC1104 and 10.5 months in the SPARK study. In the RAY study, median PFS within the TEM arm was 6.2 months; this was significantly worse than for the ibrutinib arm (hazard ratio (HR) 0.43; 95% confidence interval (CI) 0.32-0.58; p < 0.0001). Overall response rates (ORRs) assessed by an independent review committee (IRC) were similar for ibrutinib-treated patients across studies (71.9% in RAY, 69% in PCYC1104 and 62.7% in SPARK). In RAY, there was a significant advantage in ORR for ibrutinib over temsirolimus (ORR 40.4%, odds ratio (OR) 3.98, 95% CI 2.38-6.65; difference in ORR; p < 0.0001).
Health-related quality of life (HRQoL) was measured using the Functional Assessment of Cancer TherapyLymphoma (FACT-Lym) in the RAY (MCL3001) and SPARK (MCL2001) studies [15] . In the RAY study, 61.9% of ibrutinib-treated patients reported a clinically meaningful improvement; significantly fewer temsirolimus-treated patients reported clinically meaningful improvement (35.5%, p < 0.0001).
Across the three studies of ibrutinib (RAY, SPARK and PCYC1104), the most common adverse events (AEs) for ibrutinib (≥ 20% of patients) were diarrhoea, cough, fatigue, thrombocytopenia, neutropenia, peripheral oedema, nausea, muscle spasms and pyrexia.
The company's indirect comparison of ibrutinib versus single-agent chemotherapy suggested that ibrutinib was associated with a slower rate of disease progression (HR 0.19; 95% CI 0.10-0.36) and a survival benefit (HR 0.61; 95% CI 0.34-1.10) compared with single-agent chemotherapy, although the result for OS was inconclusive as it did not reach statistical significance at the 95% level. Rituximab is used in routine clinical practice in England; therefore, to account for the differential effectiveness of using rituximab alongside chemotherapy, the company performed an additional adjustment to the HR for PFS. The adjusted HR for PFS for ibrutinib versus R-chemo was estimated at 0.28.
Critique of Clinical-Effectiveness Evidence and Interpretation
The ERG believed that all relevant studies had been included in the CS [6] . The studies presented were relevant to the population, intervention and outcomes of the decision problem. The CS did not identify any RCTs that included headto-head comparisons of ibrutinib versus any of the comparators listed in the final NICE scope [9] . Temsirolimus, the comparator in the RAY trial, is not used in UK practice. The populations of the three included ibrutinib studies reflect the demographic characteristics of the R/R MCL population that would be eligible for treatment using ibrutinib in England. However, in practice, patients may have more comorbidities than those included in the studies. The studies were international, with a small proportion of patients from the UK, so there may be differences between the treatment pathways of the patients enrolled into the ibrutinib studies and those seen in current practice in England.
One of the included ibrutinib studies was an RCT (RAY), whereas the other two studies (SPARK and PCYC1104) adopted a single-arm design. All three included ibrutinib studies were open label and therefore subject to potential bias. However, all studies addressed the issue of measurement bias for the primary outcome by having an IRC assess the primary outcome. All three studies were sufficiently large to be adequately powered for their primary endpoint of PFS (RAY) or ORR (PCYC1104 and SPARK). The studies were not adequately powered to assess OS, and this outcome may have been influenced by the differential use of subsequent therapies between treatment groups. The temsirolimus arm in the RAY study had better outcomes than that in the OPTIMAL study. How much of this difference was due to temsirolimus treatment, differences in populations between trials and routine practice, and the use of other therapies or random chance was uncertain.
The company adopted a two-stage approach to estimate treatment effects for ibrutinib versus R-chemo. The ERG considered that a single-stage random effects NMA would provide a better representation of the uncertainty in the resulting treatment comparisons. Based on additional analyses undertaken by the ERG, ibrutinib was associated with a slower rate of disease progression than R-chemo but with considerable uncertainty (random effects HR 0.27; 95% credible interval (CrI) 0.06-1.26). The estimated median HRs for OS for ibrutinib versus R-chemo ranged from 0.98 to 1.96, depending on the data source used for the rituximab arm of the network (an RCT reported by Forstpointner et al. [16] , audit data from the Haematological Malignancy Research Network (HMRN) [17] or both). Given concerns regarding the evidence used to inform the indirect comparisons, the ERG advised that the results of the indirect comparison should be interpreted with caution.
Cost-Effectiveness Evidence Submitted by the Company
The company submitted a de novo health economic model that assessed the cost effectiveness of ibrutinib versus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) for the treatment of patients with R/R MCL over a 15-year (lifetime) horizon from the perspective of the UK NHS and Personal Social Services (PSS).
Costs and health outcomes were discounted at a rate of 3.5% per annum. Unit costs were valued at 2014/2015 prices. Separate subgroup analyses were presented for patients who had received one prior line of therapy (LOT) and for patients who had received two or more prior LOTs. At the time of the appraisal, a patient access scheme (PAS) in the form of a simple price discount had been agreed with the Department of Health. The value of this discount changed over the course of the appraisal. The level of the PAS is confidential; all cost-effectiveness results presented here are based on the original PAS unless otherwise stated. The company's base-case model included three health states: (1) progression free, (2) post-progression and (3) dead. The model also implicitly included a further separation between patients who were progression-free and on treatment and those who were progression-free after treatment discontinuation. The model adopted a 28-day cycle length. Within the ibrutinib group, health state transitions were modelled using parametric survivor functions fitted to data on pre-progression mortality (exponential model), PFS (Weibull model) and post-progression survival (PPS; exponential model) from a pooled dataset of the RAY, SPARK and PCYC1104 studies [18] . Time to treatment discontinuation or death (TTD/D) was also modelled using a parametric survivor function (Weibull model) but did not impact on transitions between health states. The benefits of ibrutinib versus R-CHOP were modelled using the company's indirect comparison using the RAY trial [19] (ibrutinib versus temsirolimus), the OPTIMAL trial [14] (temsirolimus versus physician's choice of single-agent chemotherapy) and audit data from the HMRN [17] (R-chemo versus chemotherapy alone). This HR was applied to both the PFS and the TTD/D curves for ibrutinib. The PPS curves for both groups were based on the pooled ibrutinib dataset [18] . Health utilities for the progression-free and post-progression states were derived from the EuroQoL-5 Dimensions, Five Levels (EQ-5D-5L) data collected within the RAY and SPARK studies [19, 20] ; the model also included a disutility associated with R-chemo toxicity, which was based on clinical opinion. Health utilities were age adjusted. The company's model included costs associated with drug acquisition, drug administration, follow-up, management of AEs, best supportive care (BSC) and death. Other resource use, including imaging, tests, biopsies, transfusions and hospitalisations, was estimated from a survey of NHS haematologists and oncologists [6] . Unit costs were taken from the Monthly Index of Medical Specialties (MIMs) [21] , the Commercial Medicines Unit (CMU) electronic market information tool (eMit) [22] and NHS reference costs [23] .
Based on a re-run of the probabilistic version of the company's base-case model by the ERG, the incremental cost-effectiveness ratio (ICER) for ibrutinib versus R-CHOP was expected to be £76,014 per quality-adjusted life-year (QALY) gained. The deterministic model produced similar results (ICER £75,317 per QALY gained). Assuming a willingness-to-pay (WTP) threshold of £50,000 per QALY gained, the company's base-case model suggested that the probability that ibrutinib produces more net benefit than R-CHOP was approximately zero. Across all but one of the company's scenario analyses, the ICER for ibrutinib versus R-chemo was greater than £70,000 per QALY gained. The only exception to this related to an analysis in which the PPS rate for R-chemo was 'calibrated' such that the overall modelled OS for R-CHOP was equal to the 8.4-month OS estimate reported within the HMRN audit [17] (ICER £59,345 per QALY gained). However, it should be noted that this was an analysis in the one prior LOT subgroup rather than the overall population.
Critique of Cost-Effectiveness Evidence and Interpretation
The ERG critically appraised the company's economic analysis and double programmed the deterministic version of the company's model. The main issues identified by the ERG are discussed below; the full critique can be found in the ERG report [2] .
Modelling Approach
The company's Markov model used three sets of transition probabilities derived from timeto-event data: (1) progression free to dead (pre-progression mortality), (2) progression free to post-progression (calculated using PFS adjusted for pre-progression mortality) and (3) post-progression to dead (PPS). While Markov models are commonly used in many areas of evaluation, the ERG had three main concerns with the company's approach:
(1) the hazard of pre-progression mortality was assumed to be constant over time, (2) the use of PPS data includes only patients who have progressed and thus may be subject to selection bias and (3) the model included a structural assumption that PPS was exponentially distributed. Furthermore, because the same PPS curve was used for both treatment groups, this use of evidence within a Markov framework imposed a direct surrogate relationship between PFS gains and OS gains, whereby, if the same pre-progression mortality curve was assumed for both groups, the incremental gain in PFS led to an equivalent incremental gain in OS. The ERG had concerns that this assumption may not be reasonable and was not adequately supported by evidence. Overall, the ERG noted that the precise modelling approach adopted is not important provided that the selected model structure does not impose inappropriate restrictions on the synthesis of evidence and the model-predicted outcomes are credible. However, the company's model-predicted OS did not provide a good visual fit to the observed Kaplan-Meier curve for ibrutinib: the model overestimated the OS for ibrutinib up to around 15.6 months and subsequently underpredicted OS beyond this timepoint (Fig. 1) . This suggested that the modelled OS trajectory for the ibrutinib group had likely been underestimated. No equivalent data were available for the R-chemo group of the model, so the accuracy of the OS prediction in this group was unknown. Given these issues, the ERG had concerns regarding the credibility of the company's results. The ERG noted that an alternative modelling approach, for example, the partitioned survival approach applied in a previous model of ibrutinib for MCL [24] , would have allowed for the inclusion of the available OS data for ibrutinib within the model and may have produced more robust predictions.
Issues Surrounding Use of Parametric Survival Modelling
The ERG highlighted several concerns regarding the company's parametric survival modelling of data on preprogression-mortality, PFS and PPS. Within the CS [6] , only a limited set of candidate survivor functions (exponential, Weibull, log normal and log logistic) were fitted to the available PFS data for ibrutinib. Other survivor functions, for example, the Gompertz, the generalised gamma, the gamma and the generalised F models, should have been considered. Following clarification, the company fitted Gompertz and generalised gamma functions to the PFS data but noted that both produced clinically implausible projections [10] . In addition, within the CS, both pre-progression mortality and PPS were assumed to be subject to a constant hazard rate. Following clarification, the company provided some evidence that the exponential model provided a reasonable fit to the pre-progression mortality data. The company also subsequently fitted alternative parametric functions to the PPS data [10] ; however, given that the model included a structural assumption that the PPS hazard was constant, these alternative functions could not be incorporated into the model, hence their impact on the ICER was unknown.
Methods for Modelling Time to Treatment Discontinuation (or Death)
The company fitted exponential, Weibull, log logistic and log normal survivor functions to data on TTD/D from the pooled ibrutinib dataset [6] ; the Weibull model was selected for use in the base-case analysis. However, all fitted curves considerably overestimated the probability of being alive and on treatment beyond the final observed datapoint within the ibrutinib dataset. Based on the company's fitted Weibull model, the probability that a patient would still be receiving treatment at 50 months was approximately 7%, whereas the KaplanMeier curve indicated that all patients had discontinued by around 32 months. Consequently, the modelled drug costs for ibrutinib, and therefore the ICER, were overestimated. The ERG considered that while the Kaplan-Meier curve is most uncertain in its tail, the best estimate of the cumulative survival probability for TTD/D would be obtained from the observed Kaplan-Meier curve rather than a parametric model, which did not provide a good fit to those data. The ERG also noted that, if censoring was truly random, additional data collection over a longer follow-up should not produce a systematic shift in the Kaplan-Meier curve.
Uncertainty Surrounding the Relative Efectiveness of Ibrutinib versus Currently Used Treatments
Given the absence of any head-to-head trials of ibrutinib versus R-chemo in patients with R/R MCL, the company's economic analysis was hinged on an indirect comparison informed by the RAY study [19] , the OPTIMAL trial [14] and the HMRN audit [17] . The ERG highlighted a number of limitations and uncertainties in the company's indirect comparison:
• The treatment effect for ibrutinib versus R-chemo, and the associated uncertainty around this estimate, could have been more meaningfully synthesised using a random effects NMA.
• The OPTIMAL trial [14] involved only single-agent chemotherapy; however, with the exception of cytarabine, all options included in the final NICE scope relate to combination chemotherapy regimens [9] . • The HR for PFS taken from the HMRN audit did not specifically relate to patients with R/R disease, did not differentiate between chemotherapy regimens and reflected only patients who responded [17] . In addition, since this study was not an RCT, the HR may be subject to confounding because of differences in patient characteristics.
• The ERG's clinical advisors suggested that rituximab plus bendamustine (R-bendamustine), rather than R-CHOP, is likely to represent the main comparator for ibrutinib, although other R-chemo regimens may be considered and clinical outcomes for R-bendamustine and R-CHOP are likely to be similar. • Pre-progression mortality for patients receiving R-chemo was not included as an outcome in the indirect comparison but was instead assumed to be equal to the rate observed in the temsirolimus arm of the RAY trial [19] . Given the absence of evidence, the validity of this assumption is unclear.
• The indirect comparison used in the health economic model is restricted to the outcome of PFS. The ERG noted that the HR for OS for R-chemo versus chemotherapy could have instead been derived using data from the RCT reported by Forstpointner et al. [16] .
In light of these issues, the ERG noted that any estimate of treatment effect for ibrutinib relative to R-chemo derived from the available evidence base will be subject to considerable uncertainty. Fig. 1 Comparison of observed and predicted overall survival for ibrutinib group 3.3.1.5 Additional Concerns Identified by the ERG The ERG noted a number of other concerns regarding the company's economic analysis. These included (1) the inappropriate exclusion of costs of subsequent therapies beyond progression, (2) the use of a blended comparison of R-chemo options with equal efficacy, (3) an assumption of an HRQoL decrement associated with R-chemo for patients that is sustained beyond discontinuation and (4) uncertainty and risk of confounding in the company's subgroup analyses based on the number of LOTs.
Additional Work Undertaken by the ERG
The ERG undertook two sets of exploratory analyses: 'Set A' and 'Set B'. Exploratory analysis Set A was undertaken using the company's Markov model. The ERG's preferred analysis involved using the HR for PFS derived from the ERG's random effects NMA, applying the observed Kaplan-Meier curve for TTD/D for the ibrutinib group and truncating the R-chemo disutility following treatment discontinuation. Based on this scenario, the probabilistic ICER for ibrutinib versus R-CHOP was £63,340 per QALY gained ( Table 1) . The ICERs for all other analyses based on this ERG-preferred model were greater than £59,952 per QALY gained. Within the one prior LOT subgroup, the ICER for ibrutinib versus R-CHOP was estimated to be £44,711 per QALY gained.
Exploratory analysis Set B involved converting the company's model structure to adopt a partitioned survival approach. This entailed using the available data for PFS and OS for ibrutinib from the pooled dataset and the estimation of treatment effects on PFS and OS derived from the ERG's NMAs. These analyses suggested that, irrespective of whether the rituximab effect is estimated using data reported by Forstpointner et al. [16] , the HRMN audit [17] or both, ibrutinib is expected to be dominated. Importantly, the ERG Table 1 Summary of key results from the company submission and the evidence review group report (using the original patient access scheme for ibrutinib in the mantle cell lymphoma indication) DSA deterministic sensitivity analysis, ERG evidence review group, HMRN Haematological Malignancy Research Network, HR hazard ratio, ICER incremental cost-effectiveness ratio, LOT line of therapy, NMA network meta-analysis, OS overall survival, PFS progression-free survival, QALY quality-adjusted life-year, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone, TTD/D time to treatment discontinuation or death
Company's economic analysis Company's base case (probabilistic) £76,014 Company's most favourable DSA (assuming R-chemo post-progression mortality probability = 0.27 (to reflect HMRN median OS of 8.4 months) using the one prior LOT subgroup)
£59,345
Company's least favourable DSA (PFS modelled using exponential distribution) £80,296 Subgroup analysis-one prior LOT subgroup £65,977 ERG exploratory analyses, Set A-based on the company's Markov model ERG exploratory analysis A1: HR for PFS derived from ERG's random effects NMA £75,094 ERG exploratory analysis A2: TTD/D for ibrutinib group based on Kaplan-Meier curve £61,472 ERG exploratory analysis A3: truncation of R-chemo disutility following treatment discontinuation £77,111 Exploratory analysis A4: ERG's preferred analysis using the company's model (combining ERG analyses A1, A2 and A3, probabilistic)
£63,340
Exploratory analysis A5i: utilities for progression-free and post-progression based on Lachaine et al. [26] , based on the ERG's preferred analysis
£60,417
Exploratory analysis A5ii: utilities for progression free and post-progression based on Yoong et al. [27] , based on the ERG's preferred analysis
£59,952
Exploratory analysis A6i: cost effectiveness of ibrutinib versus chemotherapy for rituximab-resistant patients (rituximab cost set equal to zero), based on the ERG's preferred analysis
£69,054
Exploratory analysis A6ii: cost effectiveness of ibrutinib versus chemotherapy for rituximab-resistant patients (cost of rituximab set to zero and PFS HR 0.19), based on the ERG's preferred analysis
£64,727
Exploratory analysis A7: ibrutinib versus R-CHOP in the one prior LOT subgroup using the ERG's preferred analysis, based on the ERG's preferred analysis £44,711
ERG exploratory analyses, Set B-based on the ERG's partitioned survival model and NMAs for PFS and OS Rituximab effect informed by Forstpointner et al. [16] Dominated NMA rituximab effect informed by HMRN [17] Dominated NMA rituximab effect informed by Forstpointner et al. [17] Dominated noted that this economic conclusion was likely to be a consequence of problems in robustly estimating treatment effects for OS given the weaknesses in the available evidence.
Conclusion of the ERG Report
As R/R MCL is a relatively rare disease, few real-world data are available. Only three studies of ibrutinib in patients with R/R MCL were identified, and these did not reflect treatment pathways relevant to current clinical practice in England. Based on the ERG's additional analyses, ibrutinib was associated with a slower rate of disease progression than R-chemo (random effects HR 0.27; 95% CrI 0.06-1.26), although the result was inconclusive as it did not reach statistical significance at the 95% level. The estimated median HRs for OS for ibrutinib versus R-chemo ranged from 0.98 to 1.96, depending on the data source used for the rituximab arm of the network. This illustrates the high level of uncertainty for this comparison. Based on analyses of the company's model undertaken by the ERG (including the company's original PAS), the ICER for ibrutinib versus R-chemo is likely to be greater than £59,952 per QALY gained in the overall R/R MCL population. The cost-effectiveness profile of ibrutinib appears to be improved in the one prior LOT subgroup but may be subject to confounding due to the post hoc definition of the subgroup and subject to bias due to the poor fit of the Weibull function used to model PFS.
Methodological Issues
The ERG noted problems relating to the robustness of the indirect comparison for OS. The ERG considered that a balance exists in that the company's PFS-based Markov model made a number of restrictive structural assumptions that led to a poor model fit to the available OS data for ibrutinib, whereas the ERG's partitioned survival analysis (exploratory analysis Set B) provided a better fit to the OS data but involved using the outputs of a highly uncertain NMA.
National Institute for Health and Care Excellence (NICE) Guidance
The AC reviewed the data available on the clinical and cost effectiveness of ibrutinib, having considered evidence on the nature of R/R MCL and the value placed on the benefits of ibrutinib by people with the condition, those who represent them and clinical experts. It also took into account the effective use of NHS resources. The first ACD (published August 2016) did not recommend ibrutinib within its marketing authorisation for the treatment of adult patients with R/R MCL [25] . The AC noted that the ICERs presented by the company, which incorporated the original PAS for ibrutinib, were substantially above the range normally considered a cost-effective use of NHS resources. Following the first ACD, the company submitted an additional analysis of the HMRN dataset and updated the PAS for ibrutinib. The AC considered that this new analysis provided some reassurance regarding the company's modelling method but noted that the ICER was higher than the committee could accept as a cost-effective use of NHS resources.
Following the second ACD, the company submitted a response that included a newer data-cut from the RAY study and requested routine commissioning for ibrutinib within the one prior LOT subgroup, based on an ICER of £49,849 per QALY gained. In December 2017, NICE published its FAD [3] , which made the following recommendation: "Ibrutinib is recommended as an option for treating relapsed or refractory mantle cell lymphoma in adults, only if:
• they have had only one previous line of therapy and • the company provides ibrutinib with the discount agreed in the commercial access agreement with NHS England".
Consideration of Clinical Effectiveness and Cost-Effectiveness Issues
This section discusses the key issues considered by the AC. The full list can be found in the FAD [3] .
Clinical Trial Evidence
The AC noted that the evidence on the clinical effectiveness of ibrutinib came from one RCT (RAY) and two single-arm studies (SPARK and PCYC1104). It considered that RAY is not strictly relevant to NHS practice because temsirolimus is not routinely used in the UK and noted the absence of trials comparing ibrutinib with any comparator defined in the NICE scope. The AC concluded the studies were of a reasonable quality but were limited by the lack of a comparison against a treatment used in UK clinical practice. The AC noted that at median follow-up of 20 months in RAY, median PFS was statistically significantly longer for ibrutinib than for temsirolimus (14.6 versus 6.2 months; HR 0.43; 95% CI 0.32-0.58; p < 0.0001). At the time of the first AC meeting, the OS data from RAY were immature and median OS had not yet been reached in the ibrutinib arm. The AC understood that the OS results could be confounded, as 23% of patients in the temsirolimus arm switched to subsequently receive ibrutinib and the use of subsequent anticancer systemic therapies differed between treatment groups. Following consultation on the second ACD, the AC considered updated data from RAY provided by the company; they noted that the updated results were consistent with the earlier data and that median OS had now been reached (30.3 months for ibrutinib compared with 23.5 months for temsirolimus; HR 0.74; 95% CI 0.54-1.02). The AC concluded that the results from RAY suggest that ibrutinib significantly improves PFS compared with temsirolimus but that the OS benefits remain uncertain.
Indirect Comparison
The AC understood the company's indirect comparison using data from RAY, OPTIMAL and the HMRN audit resulted in an HR for PFS for ibrutinib versus R-chemo of 0.28. The AC acknowledged the limitations of the indirect comparison and noted that the ERG did not agree with the company's two-stage approach to estimating treatment effects. The AC noted that, because of concerns about the evidence used to inform the indirect comparisons, the ERG considered that the results of both the company's analyses and the ERG's analyses should be interpreted with caution. The AC concluded that considerable uncertainty was associated with the indirect comparisons and that the benefit of ibrutinib compared with R-chemo was unclear, although it accepted that the available evidence and experience from clinical practice strongly suggested that ibrutinib is more effective.
Subgroups
The AC discussed the efficacy results for subgroups of patients based on the number of previous LOTs. It noted that the results suggested greater efficacy in patients who received ibrutinib after only one previous LOT compared with two or more previous LOTs. The clinical expert also stated that ibrutinib is particularly beneficial after the first relapse. The AC considered the updated RAY data and noted that these provided further evidence of a greater benefit of ibrutinib when taken after only one previous LOT. The AC understood that the data were potentially confounded by patients in the temsirolimus arm switching to ibrutinib and that the subgroups were defined post hoc. However, the AC noted responses to the ACD from professional groups that stated that evidence from clinical practice supports the RAY results and that earlier use of ibrutinib in R/R disease is the most beneficial. The AC concluded that the evidence from RAY and clinical experience suggests that ibrutinib is most effective in people who have had only one previous LOT.
Company's Economic Analysis
The AC noted that the company had developed a Markov model comparing ibrutinib with R-chemo, comprising three states (pre-progression, post-progression and death) and that this approach had been used in previous appraisals. The AC was aware that OS data from the ibrutinib studies were not directly extrapolated but were modelled using PFS and PPS data from the pooled ibrutinib dataset. The AC considered that the company's approach was appropriate given the immaturity of the OS data available. The AC considered the ERG's critique of the company's model. It noted the ERG's comments that the company's Markov approach imposed structural constraints, which did not make the best use of the trial data on survival, and that the OS predicted by the model did not provide a good visual fit to the observed Kaplan-Meier OS curve from the trials. The AC understood that the ERG had explored the effect of using a partitioned survival approach in their exploratory analysis (Set B) but was concerned that this resulted in efficacy estimates for R-chemo that were higher than those for ibrutinib, giving higher QALY gains for R-chemo than ibrutinib, which were implausible. The AC concluded that the results of the partitioned survival analysis were not clinically plausible, acknowledging the ERG's comments that they were associated with major uncertainty because they relied on the outputs of a highly uncertain meta-analysis.
The AC re-examined the company's Markov approach, which it considered led to more plausible results. The AC noted that, in the company's base-case analysis, which incorporated the updated PAS, the ICER for ibrutinib versus R-chemo was £62,650 per QALY gained. The AC also noted that all but one of the company's scenario analyses produced ICERs that were above £59,000 per QALY gained. In this one scenario, the company applied an HR to PPS for R-chemo, which was adjusted to be as close as possible to the anticipated survival based on the results of the HMRN audit. This resulted in an ICER of £49,849 per QALY gained. However, the AC understood that time-toevent estimates for PFS and PPS for ibrutinib were taken from the one prior LOT subgroup, and therefore that the analysis reflected this subgroup.
The AC noted that the ERG's exploratory analyses using the company's model (Set A) made adjustments to some of the parameter values in the company's model, which mostly resulted in lower ICERs than those presented by the company. However, the AC was minded not to accept the results of the ERG's preferred base case for Set A because these represented the extreme (lowest) end of the ERG's wide estimate of possible ICERs, depending on the model and parameters used. The AC concluded that the ICERs presented by the company for the whole population of people with R/R MCL, incorporating the updated PAS for ibrutinib, were above the range normally considered a cost-effective use of NHS resources (£20,000-30,000 per QALY gained). The AC recognised that ibrutinib has several benefits that may not be reflected in the QALY calculations (oral administration, manageable adverse reactions and low toxicity); however, it did not consider these would be sufficient to lower the ICER for the whole population to within the range normally considered cost effective.
Noting its conclusion that trial evidence and clinical experience suggest that ibrutinib is most effective in people who have had only one prior LOT, the AC assessed whether ibrutinib could be considered cost effective in this subgroup of patients. It noted that the company's ICER of £49,849 per QALY gained may be a conservative estimate because updated trial data from RAY suggest the model underestimates survival for this subgroup. The AC also noted that OS in RAY may have been confounded by the switching of patients in the temsirolimus arm to the ibrutinib arm. The AC concluded that the most plausible ICER in this group of patients was likely to be lower than the company's estimate of £49,848 per QALY gained.
The AC noted that the OS estimates presented for people with R/R MCL ranged from 5.2 to 9.7 months. It also accepted that there was enough evidence to indicate that ibrutinib offers an extension to life of at least an additional 3 months compared with current NHS treatment. On this basis, the AC concluded that ibrutinib met all the criteria to be considered a life-extending end-of-life treatment.
Appraisal Committee's Key Conclusion
The AC concluded that the most plausible ICER for the one prior LOT subgroup is likely to be lower than the company's estimate of £49,848 per QALY gained.
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